NORDMEDICA A/S: Financial statements 2017
CVR: 27299032
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
NORDMEDICA A/S (CVR 27299032) has filed annual accounts for 2017. In 2017, the company reported a gross profit of EUR 2,950,159 and a net result of EUR 2,233,637 compared with EUR 1,014,285 the year before. That is an increase of 114.3% compared with the year before. Equity in the 2017 report amounted to EUR 8,289,413. The solvency ratio was 92.4%.
- Gross Profit
- EUR 2,950,159
- Profit/Loss
- EUR 2,233,637
- Equity
- EUR 8,289,413
- Total Assets
- EUR 8,969,337
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 3M EUR | 2.2M EUR | 8.3M EUR | - |
| 2016 | - | 1.4M EUR | 1M EUR | 6.1M EUR | - |
| 2015 | - | 1.3M EUR | 1M EUR | 5M EUR | - |
| 2014 | - | 1.7M EUR | 1.2M EUR | 4M EUR | - |
| 2013 | - | 2.2M EUR | 1.6M EUR | 2.8M EUR | - |
Official annual report
Keep an eye on NORDMEDICA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
NORDMEDICA A/S has published its annual report for 2016. Gross profit came to DKK 1,376,844, and the net result was DKK 1,014,285.
As of March 15, 2017, Thomas Willem Johannes Nicolaas Calis has joined the board of directors of NORDMEDICA A/S.
As of March 15, 2017, Willem Frans van Doorn has left the board of directors of NORDMEDICA A/S.
About NORDMEDICA A/S
NORDMEDICA A/S is a Danish company of the type Aktieselskab based in Charlottenlund, founded in 2003. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named NORDMEDICA ApS and VICH 7232 ApS. The management consists of Michael van Woensel. The board consists of Thomas Willem Johannes Nicolaas Calis (chair), Anna Novikova and Michael van Woensel. The company is owned by Mperium B.V.. The company has 0 employees (2012). In 2025, the company reported a gross profit of EUR -25,989 and a net result of EUR -20,289 compared with EUR 616,171 the year before. Equity in the 2025 report amounted to EUR 877,251.
